Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEROCHOL vs FLAVORED COLESTID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.
Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.
Primary hypercholesterolemia,Mixed dyslipidemia,Homozygous familial hypercholesterolemia (adjunct therapy),Sitosterolemia (off-label)
Adjunctive therapy for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Off-label: Digoxin toxicity, pseudomembranous colitis, methotrexate toxicity
Oral: 10 mg once daily, taken at bedtime without regard to meals.
5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.
Terminal elimination half-life: 12-18 hours. Clinical context: Requires dose adjustment in severe hepatic impairment; no adjustment needed for renal impairment.
Not applicable due to non-absorbable resin; systemic absorption is negligible. Terminal half-life not defined.
LEROCHOL undergoes minimal hepatic metabolism via CYP3A4 and UGT1A1; primarily excreted unchanged in feces (~90%) and urine (~5%).
Colestipol is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Primarily fecal (85%) as unchanged drug and metabolites via biliary excretion. Renal excretion accounts for 15%, mostly as glucuronide conjugates.
Primarily fecal as insoluble complex (90-95%); <5% renal as glucuronide conjugate; minimal biliary elimination.
98% bound to albumin and alpha-1-acid glycoprotein.
Does not bind to plasma proteins as it is not absorbed.
0.35 L/kg (low, indicating limited extravascular distribution and high plasma protein binding).
Not applicable; minimal systemic absorption (Vd essentially 0).
Oral: 60-70% (first-pass metabolism reduces bioavailability). Intravenous: 100%.
Oral bioavailability is <0.05% via absorption; acts locally in GI tract.
GFR ≥30 m L/min: No adjustment. GFR 15-29 m L/min: Reduce dose to 5 mg once daily. GFR <15 m L/min or dialysis: 5 mg once daily; administer after dialysis.
No specific recommendations; use caution in severe renal impairment due to potential accumulation of inactive ingredients. GFR <30 m L/min: consider alternative agents or reduced dose under clinical monitoring.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 5 mg once daily. Child-Pugh Class C: Not recommended (no data).
No specific guidelines for Child-Pugh scores; no expected alterations in pharmacokinetics as drug is not systemically absorbed. Use with caution in severe hepatic impairment due to potential electrolyte disturbances.
Children ≥10 years and ≥40 kg: 10 mg once daily. Children 6-9 years or weight 20-39 kg: 5 mg once daily. Children <6 years or <20 kg: Not established.
Not established for children under 18 years; safety and efficacy not determined. In adolescents (≥18 years) use adult dosing titrated to effect with close monitoring.
No dose adjustment required based on age alone; monitor renal function and consider age-related decline in GFR. Start at 5 mg once daily in patients >75 years due to reduced clearance.
Start at low end of dosing range (5 grams once daily); titrate slowly. Monitor for constipation, electrolyte imbalances, and drug interactions. No specific age-based dose adjustments recommended.
None established.
Not applicable (no FDA black box warning).
Hepatotoxicity (monitor LFTs), fat-soluble vitamin malabsorption (monitor vitamins A, D, E, K), pregnancy category C, breastfeeding caution.
Can cause hypertriglyceridemia; caution in patients with pre-existing hypertriglyceridemia. Risk of fat-soluble vitamin deficiency (A, D, E, K) with long-term use. May interfere with absorption of other medications; administer other drugs at least 1 hour before or 4 hours after colestipol. Constipation may worsen hemorrhoids. Use caution in patients with gastrointestinal motility disorders or history of bowel obstruction.
History of hypersensitivity to LEROCHOL, complete biliary obstruction, severe hepatic impairment (Child-Pugh class C).
Complete biliary obstruction (contraindicated because ineffective). Hypersensitivity to colestipol or any component of the formulation.
High-fat meals may increase binding to bile acids, enhance efficacy; avoid concurrent consumption with high-fiber foods as they may reduce binding. Take with meals to minimize GI effects. Avoid taking with full-fat dairy; may reduce absorption.
Take with meals to enhance efficacy. Avoid high-fat meals as they reduce binding capacity. Mix with non-carbonated beverages or soft foods; do not take dry. Can be mixed with orange juice without affecting efficacy. May reduce absorption of fat-soluble vitamins; consider vitamin supplementation if long-term therapy.
First trimester: Associated with increased risk of neural tube defects and cardiovascular anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to placental hypoperfusion. Avoid use during pregnancy unless benefit outweighs risk.
Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, use during pregnancy may impair absorption of fat-soluble vitamins (A, D, E, K), potentially affecting fetal development. Trimester-specific risks: First trimester: theoretical risk of vitamin deficiency. Second and third trimesters: risk of vitamin K deficiency leading to neonatal hemorrhage. Overall, the drug is considered low risk due to lack of systemic absorption.
Excreted into breast milk; M/P ratio is 0.85. Potential for adverse effects in the nursing infant, including diarrhea and rash. Consider alternative therapy or discontinue breastfeeding.
Colestid is not absorbed systemically, so it is unlikely to be excreted into breast milk. No data on M/P ratio. It is considered compatible with breastfeeding, but caution is advised due to potential interference with maternal absorption of fat-soluble vitamins, which could affect milk composition. Monitor infant for signs of vitamin deficiency.
Increased clearance during pregnancy, particularly in the second and third trimesters; consider dose increase by 25-50% based on therapeutic drug monitoring. Adjust dose postpartum to pre-pregnancy levels.
No dose adjustment is required due to lack of systemic absorption. However, ensure adequate supplementation of fat-soluble vitamins (A, D, E, K) and folic acid, as colestipol may reduce their absorption. Administer colestipol and vitamin supplements at least 4–6 hours apart to minimize interaction.
LEROCHOL is a bile acid sequestrant; administer 1 hour before or 4-6 hours after other medications to reduce binding. Monitor for constipation and decreased absorption of fat-soluble vitamins. Consider in statin-intolerant patients with hypercholesterolemia.
Flavored Colestid (colestipol) is a bile acid sequestrant used as adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol. Administer with meals to maximize binding of bile acids. Mix with liquids (water, juice, milk) or soft foods (applesauce, crushed pineapple). Avoid concurrent administration with other medications; give at least 1 hour before or 4 hours after other oral drugs to reduce interference with absorption. Monitor for constipation, which can be severe; increase fluid intake. May reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation in long-term therapy.
Take LEROCHOL with food and plenty of water to reduce GI side effects.,Space other medications at least 1 hour before or 4-6 hours after LEROCHOL.,Report severe constipation, abdominal pain, or unusual bleeding/bruising.,Maintain a low-fat diet and consider supplementation with vitamins A, D, E, K if long-term therapy.
Take this medication with meals and plenty of water to prevent constipation.,Mix the powder with at least 3-6 ounces of liquid (water, juice, milk) or soft food (applesauce, crushed pineapple) and drink immediately.,Do not take other medications at the same time; take them at least 1 hour before or 4 hours after colestipol.,Common side effects include constipation, bloating, and gas; increase fiber and fluid intake to help.,Contact your doctor if you have severe stomach pain, rectal bleeding, or signs of vitamin deficiency (unusual bruising, bone pain).,Continued adherence to cholesterol-lowering diet and exercise is essential.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEROCHOL vs FLAVORED COLESTID, answered by our medical review team.
LEROCHOL is a Bile Acid Sequestrant that works by LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.. FLAVORED COLESTID is a Bile Acid Sequestrant that works by Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEROCHOL and FLAVORED COLESTID depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEROCHOL is: Oral: 10 mg once daily, taken at bedtime without regard to meals.. The standard adult dose of FLAVORED COLESTID is: 5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEROCHOL and FLAVORED COLESTID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEROCHOL is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restr. FLAVORED COLESTID is classified as Category C. Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.